title: Is flecainide dangerous in long QT-3 patients?
abstract: Mutations of the cardiac sodium channel gene, SCN5A, are present in both long-QT and Brugada syndromes. Flecainide is used as a provocative test to unmask the electrocardiogram (ECG) phenotype of the Brugada syndrome, as well as long-term treatment for long QT-3 syndrome, since it shortens the QT interval. We report a case where oral flecainide induced syncope with a Brugada ECG pattern in a patient with known long QT-3 syndrome.
authors.affiliation: Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: Roy
authors.initials: R
authors.lastname: Beinart
authors.forename: Athanasios
authors.initials: A
authors.lastname: Michailidis
authors.forename: Osnat T
authors.initials: OT
authors.lastname: Gurevitz
authors.forename: Michael
authors.initials: M
authors.lastname: Glikson
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D053840:Brugada Syndrome / Q000150:complications / Q000175:diagnosis*; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D005424:Flecainide / Q000009:adverse effects*; D006801:Humans; D008133:Long QT Syndrome / Q000150:complications / Q000175:diagnosis*; D013575:Syncope / Q000139:chemically induced* / Q000175:diagnosis*; D055815:Young Adult
chemical_list: D000889:Anti-Arrhythmia Agents; D005424:Flecainide